- Trial Phase
- Approved (marketed; sBLA label expansion approved May 4, 2026)
- Time to Market
- Already approved and on the market; the pediatric label expansion took effect May 2026.
- Why 4/10
- The next hard, dated binary for ASCENIV — the FDA sBLA decision on the pediatric label expansion — already passed on May 4, 2026; no new PDUFA or pivotal readout is scheduled in the next ~12 months, so the score sits at the 3-5 range for an approved, commercializing drug (4, because ASCENIV is essentially ADMA's entire revenue story and litigation news can still move the stock).
Watch the securities-fraud litigation (class period Aug 9, 2024–Mar 25, 2026) and ADMA's quarterly disclosures of distributor inventory vs. end-user demand — that is the crux of the channel-stuffing allegation. The next scheduled market event is Q3 2026 earnings (~November); with ~9.8% of estimated shares outstanding sold short (days-to-cover ~8.8), any settlement, dismissal, or demand-data surprise could swing the stock sharply.
Price Chart
Executive Summary
ASCENIV is ADMA Biologics' lead and dominant product, an FDA-approved intravenous immune globulin (IVIG) for primary humoral immunodeficiency; on May 4, 2026 the FDA approved a label expansion to pediatric patients aged 2+. It drove record 2025 results (revenue ~$510M, +20% YoY). The stock has been volatile since a March 2026 Culper Research short-seller report accused ADMA of channel stuffing, followed by securities-fraud class actions (announced by Berger Montague and other firms) covering Aug 9, 2024–Mar 25, 2026; ADMA has denied the allegations.
How It Works
ASCENIV is a blood-plasma product — a 10% liquid concentrate of infection-fighting antibodies (immune globulin) purified from human donor plasma and given intravenously. Patients with primary humoral immunodeficiency cannot make enough of their own antibodies, so ASCENIV supplies ready-made ones to prevent infections.
Trial Status
ASCENIV is a commercial product for primary humoral immunodeficiency (PI). On May 4, 2026 the FDA approved a supplemental BLA expanding the label to PI patients aged 2 years and older (previously 12+), fulfilling a post-marketing commitment. No new pivotal trials appear in locally ingested clinical-trial records.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report (~November 2026)
- Securities litigation developments (motion to dismiss, pleadings, discovery, any settlement) — lead-plaintiff deadline was Aug 10, 2026
- Semi-monthly FINRA short-interest prints
- Any further label-expansion, supply-capacity, or demand-data disclosures from ADMA — no FDA PDUFA or pivotal readout is scheduled in the next ~12 months